TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NATCOPHARM Stock 12 Month Forecast
There Are No Analyst Ratings for IN:NATCOPHARM In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
NATCOPHARM Financial Forecast
NATCOPHARM Earnings Forecast
Next quarter’s earnings estimate for NATCOPHARM is ₹5.27 with a range of ₹1.20 to ₹8.80. The previous quarter’s EPS was ₹29.00. NATCOPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.
Next quarter’s earnings estimate for NATCOPHARM is ₹5.27 with a range of ₹1.20 to ₹8.80. The previous quarter’s EPS was ₹29.00. NATCOPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.
NATCOPHARM Sales Forecast
Next quarter’s sales forecast for NATCOPHARM is ₹6.87B with a range of ₹5.26B to ₹9.50B. The previous quarter’s sales results were ₹13.63B. NATCOPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.
Next quarter’s sales forecast for NATCOPHARM is ₹6.87B with a range of ₹5.26B to ₹9.50B. The previous quarter’s sales results were ₹13.63B. NATCOPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NATCOPHARM has Performed in-line its overall industry.
Dolat Capital Downgrades Natco Pharma Ltd (NTCPH:IN) to Sell (4)Dolat Capital analyst Rashmi Shetty downgraded Natco Pharma Ltd (NTCPH:IN) from Reduce (3) to Sell (4) with a price target of INR913.00 (from INR1,458.00).
Dolat Capital Downgrades Natco Pharma Ltd (NTCPH:IN) to Sell (4)Dolat Capital analyst Rashmi Shetty downgraded Natco Pharma Ltd (NTCPH:IN) from Reduce (3) to Sell (4) with a price target of INR913.00 (from INR1,458.00).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +11.90% per trade.
Copying Abdulkader Puranwala's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.00% per trade.
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +2.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NATCOPHARM Analyst Recommendation Trends
Rating
May 25
Jul 25
Aug 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
1
2
1
4
4
Hold
1
1
1
0
0
Sell
1
2
2
2
1
Strong Sell
0
0
0
0
0
total
3
5
4
6
5
In the current month, NATCOPHARM has received 4Buy Ratings, 0Hold Ratings, and 1Sell Ratings. NATCOPHARM average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
NATCOPHARM Stock Forecast FAQ
What is IN:NATCOPHARM’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:NATCOPHARM’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:NATCOPHARM, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NATCO Pharma Limited a Buy, Sell or Hold?
Currently, no data Available
What is NATCO Pharma Limited’s share price target?
Currently, no data Available
What do analysts say about NATCO Pharma Limited?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of NATCO Pharma Limited?
To buy shares of IN:NATCOPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.